MX2023012971A - Agonistas del receptor de orexina y sus usos. - Google Patents
Agonistas del receptor de orexina y sus usos.Info
- Publication number
- MX2023012971A MX2023012971A MX2023012971A MX2023012971A MX2023012971A MX 2023012971 A MX2023012971 A MX 2023012971A MX 2023012971 A MX2023012971 A MX 2023012971A MX 2023012971 A MX2023012971 A MX 2023012971A MX 2023012971 A MX2023012971 A MX 2023012971A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- receptor agonists
- orexin receptor
- formula
- pharmaceutically acceptable
- Prior art date
Links
- 229940127340 Orexin Receptor Agonists Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000002512 Orexin Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 108060005714 orexin Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183321P | 2021-05-03 | 2021-05-03 | |
| PCT/EP2022/061851 WO2022233872A1 (en) | 2021-05-03 | 2022-05-03 | Orexin receptor agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012971A true MX2023012971A (es) | 2024-01-16 |
Family
ID=81940742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012971A MX2023012971A (es) | 2021-05-03 | 2022-05-03 | Agonistas del receptor de orexina y sus usos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240254143A1 (https=) |
| EP (1) | EP4334323A1 (https=) |
| JP (1) | JP2024516033A (https=) |
| KR (1) | KR20240004802A (https=) |
| CN (1) | CN117616030A (https=) |
| AU (1) | AU2022269811A1 (https=) |
| BR (1) | BR112023022050A2 (https=) |
| CA (1) | CA3217403A1 (https=) |
| IL (1) | IL308099A (https=) |
| MX (1) | MX2023012971A (https=) |
| TW (1) | TW202309051A (https=) |
| WO (1) | WO2022233872A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| WO2023081094A1 (en) * | 2021-11-04 | 2023-05-11 | University Of Washington | Novel spirocyclic compounds as klhdc2 ligands |
| EP4658660A1 (en) | 2023-01-31 | 2025-12-10 | Jazz Pharmaceuticals Ireland Limited | Macrocyclic orexin receptor agonists and uses thereof |
| CN116478076A (zh) * | 2023-04-26 | 2023-07-25 | 南京优氟医药科技有限公司 | 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法 |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69318854T2 (de) * | 1993-03-04 | 1998-10-08 | Pfizer | Spiroazacyclischderivate als substanz p antagonisten |
| DE69923744T2 (de) * | 1998-10-23 | 2006-02-23 | Pfizer Inc. | 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten |
| WO2011076747A1 (en) * | 2009-12-21 | 2011-06-30 | Novartis Ag | Diaza-spiro[5.5]undecanes as orexin receptor antagonists |
| US20120101110A1 (en) * | 2010-10-26 | 2012-04-26 | Sangamesh Badiger | Diaza-spiro[5.5]undecanes |
| PL3411358T3 (pl) * | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| JP7413261B2 (ja) * | 2018-06-29 | 2024-01-15 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| US11098029B2 (en) * | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
-
2022
- 2022-05-03 KR KR1020237041381A patent/KR20240004802A/ko active Pending
- 2022-05-03 MX MX2023012971A patent/MX2023012971A/es unknown
- 2022-05-03 CN CN202280045968.9A patent/CN117616030A/zh active Pending
- 2022-05-03 WO PCT/EP2022/061851 patent/WO2022233872A1/en not_active Ceased
- 2022-05-03 JP JP2023567888A patent/JP2024516033A/ja active Pending
- 2022-05-03 EP EP22727800.9A patent/EP4334323A1/en active Pending
- 2022-05-03 US US18/558,245 patent/US20240254143A1/en active Pending
- 2022-05-03 AU AU2022269811A patent/AU2022269811A1/en active Pending
- 2022-05-03 TW TW111116714A patent/TW202309051A/zh unknown
- 2022-05-03 IL IL308099A patent/IL308099A/en unknown
- 2022-05-03 CA CA3217403A patent/CA3217403A1/en active Pending
- 2022-05-03 BR BR112023022050A patent/BR112023022050A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024516033A (ja) | 2024-04-11 |
| AU2022269811A1 (en) | 2023-11-16 |
| BR112023022050A2 (pt) | 2023-12-26 |
| US20240254143A1 (en) | 2024-08-01 |
| EP4334323A1 (en) | 2024-03-13 |
| CN117616030A (zh) | 2024-02-27 |
| KR20240004802A (ko) | 2024-01-11 |
| WO2022233872A1 (en) | 2022-11-10 |
| TW202309051A (zh) | 2023-03-01 |
| IL308099A (en) | 2023-12-01 |
| CA3217403A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012971A (es) | Agonistas del receptor de orexina y sus usos. | |
| MX2023015074A (es) | Agonistas de sulfonamidas del receptor de orexina y sus usos. | |
| EP4458834A3 (en) | Heterocyclic glp-1 agonists | |
| MX2023014630A (es) | Activadores de dimetoxifenilalquilamina de receptores de serotonina. | |
| EP4699609A3 (en) | Heterocyclic glp-1 agonists | |
| MX2023001311A (es) | Agonistas heterociclicos de glp-1. | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2025004220A (es) | Compuestos triciclicos y sus usos | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| MX2020000268A (es) | Agonista de fxr. | |
| MX2025015186A (es) | Inhibidores de pi3k y uso de estos | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| PH12014500937A1 (en) | 5-ht 1a receptor substype agonist | |
| MX2024003738A (es) | Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico. | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2025005223A (es) | Agonistas del estimulador de genes de interferon (sting) | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. | |
| MX2024014790A (es) | Agonistas del receptor macrocíclico de orexina y sus usos | |
| MX2024012470A (es) | Inhibidores de cinasas dependientes de ciclina 9 (cdk9) | |
| CR20230218A (es) | Nuevos derivados de indazol acetileno | |
| EP4670791A3 (en) | Compounds and compositions for treating conditions associated with lpa receptor activity | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| GEAP202516217A (en) | Compounds and compositions as sppl2a inhibitors | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 |